Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis



Status:Completed
Conditions:Osteoporosis
Therapuetic Areas:Rheumatology
Healthy:No
Age Range:55 - Any
Updated:6/9/2018
Start Date:November 7, 2012
End Date:January 7, 2015

Use our guide to learn which trials are right for you!

A Randomized Double-blind Study to Evaluate the Safety and Efficacy of Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates

This study will compare the effectiveness of denosumab treatment every 6 months with once
yearly zoledronic acid treatment on bone mineral density (BMD) at various skeletal sites.


Inclusion Criteria:

- Ambulatory postmenopausal women.

- Age 55 years or older

- Subject has provided informed consent prior to any study specific procedures

- Received oral bisphosphonate therapy for osteoporosis at least 2 years prior to
screening visit

- Screening BMD (g/cm²) values at the lumbar spine, total hip or femoral neck values of
equal to or less than those listed in the protocol.

- At least 2 lumbar vertebrae and one hip must be evaluable by dual energy x-ray
absorptiometry (DXA) at the screening visit

Exclusion Criteria:

- Received other osteoporosis treatment or bone active treatment

- Evidence of history of any of the following:

- hyperthyroidism (stable on antithyroid therapy is allowed)

- hypothyroidism (stable on thyroid replacement therapy is allowed)

- hypo- or hyperparathyroidism

- hypo- or hypercalcemia based on the central laboratory reference ranges

- Recent tooth extraction (within 6 months of screening visit)

- Paget disease of bone (subject report or chart review)

- other bone diseases which affect bone metabolism (eg, osteopetrosis, osteogenesis
imperfecta) (chart review)

- Abnormalities of the following per central laboratory reference ranges:

- vitamin D deficiency (25[OH] vitamin D level < 20 ng/mL), repletion will be
allowed and subjects may be re-screened

- hypercalcemia

- elevated transaminases ≥ 2.0 x upper limits of normal (ULN)

- History of any solid organ or bone marrow transplant

- Malignancy (except nonmelanoma skin cancers, cervical or breast ductal carcinoma in
situ) within the last 5 years

- Known intolerance to calcium or vitamin D supplements

- Self-reported alcohol or drug abuse within 12 months prior to screening

- Currently receiving treatment in another investigational device or drug study, or less
than 30 days since ending treatment on another investigational device or drug study(s)

- History or evidence of any other clinically significant disorder, condition or disease
that in the opinion of the Investigator or Amgen physician, if consulted, would pose a
risk to subject safety or interfere with the study evaluation, procedures or
completion
We found this trial at
10
sites
?
mi
from
Santa Monica, CA
Click here to add this to my saved trials
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
?
mi
from
Detroit, MI
Click here to add this to my saved trials
?
mi
from
Hagerstown, MD
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Lakewood, CO
Click here to add this to my saved trials
?
mi
from
Longmont, CO
Click here to add this to my saved trials
?
mi
from
Maroubra,
Click here to add this to my saved trials
?
mi
from
Washington,
Click here to add this to my saved trials
West Haverstraw, New York 10993
?
mi
from
West Haverstraw, NY
Click here to add this to my saved trials